Han Yu Pharmaceutical: The agreements signed in the first half of the year for 180 million yuan and 327 million yuan of GLP-1 raw material orders are both framework agreements.

On June 26, Han Yu Pharmaceuticals stated on the interactive platform that the GLP-1 raw material orders of 180 million yuan and 327 million yuan signed in the first half of this year were all framework agreements, and the specific purchase amount is subject to the actual orders issued by the customers. At the same time, the impact of the performance of this framework agreement on the company's net profit needs to be comprehensively determined based on factors such as the progress of subsequent order execution and income recognition. Please refer to the company's periodic reports for specific details. The company will strictly fulfill its duty of information disclosure, and any significant developments will be promptly announced.